Stopping Aggressive Breast Cancer Metastasis

Australian researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute published a study on August 21, 2026, in EMBO Molecular Medicine identifying a promising new approach to stop aggressive triple-negative breast cancer from spreading. The research demonstrates that restoring a naturally occurring molecule called miR-342 significantly reduces the metastasis of cancer cells to distant organs such as the lungs and bones in pre-clinical models. The authors emphasize that the primary danger of triple-negative breast cancer stems from its lack of common molecular targets like estrogen receptors, progesterone receptors, and HER2, making standard targeted therapies ineffective and metastasis life-threatening. The study found that low levels of miR-342 combined with high activity in the cancer-promoting E2F pathway mark patients at much higher risk for metastatic disease. The essence of the strategy involves repurposing an existing cancer drug called palbociclib, which is a CDK4/6 inhibitor normally used for advanced hormone receptor-positive breast cancer. When administered in models with low miR-342 levels, palbociclib successfully suppressed the growth of metastatic tumors by preventing microscopic deposits from developing into secondary cancers. This discovery provides a personalized treatment framework for the 10-15 percent of Australian breast cancer diagnoses categorized as triple-negative, opening the door for future clinical trials to improve patient survival rates and offer targeted therapeutic options after the cancer has spread.